A judge has ordered Guardant to pay royalties to Twinstrand Biosciences after losing a patent dispute — this hits the very tests that generate the company's revenue, so it's a lasting cost, not a one-off headline. Royalty payments will squeeze margins qua

Verdict: the royalty thesis has fuel, but the tape hasn't lit it — wait

The thesis has a real anchor: per Investor's Business Daily (August 24, 2026), a judge ordered Guardant to pay Twinstrand royalties on the very tests that drive revenue, and GH was already losing money — a $416.3M net loss on $982.0M of 2025 revenue, negative equity of $99.3M, and free cash flow in the 7th percentile of 757 Health Care peers. But the counter-evidence is substantial: revenue grew 11.0% sequentially to $335.0M in the June 2026 quarter, gross margin sits at 65.4% and has climbed from 59.7% in 2023, and liquidity is strong with a current ratio of 4.8 and $378.2M in cash — this is a slow-burn story, not a crisis. The tape actively refutes the short thesis right now: the stock closed at $167.88, roughly 48% above its 200-day average of $113.66, with RSI (14) at 64.0 and MACD positive, so no entry condition is live. The insider selling signal ($104.4M net, per the filing covering the period ended June 30, 2026) is thin — only two holders covering 3,588 shares — and predates the ruling, so it is suggestive, not confirmatory. A scope note: the rule set could not be evaluated because GH daily market-data coverage could not be verified, so no robust parameter setup was established. Wait for either the entry conditions to confirm or the November 2026 quarter filing to show whether the royalty compounds the widening cash burn.

Trade now: wait — the short-side trend setup has not triggered on GH

GH last closed at $167.88, within roughly 2% of its range high and about 48% above its 200-day average of $113.66. Despite the bearish royalty thesis, the tape is not confirming it: RSI (14) sits at 64.0, well above the at-or-below-50 entry condition, and MACD (12,26,9) at 3.68 has not crossed below zero. Of the four entry conditions, only ADX (14) is close — 19.2 against the above-20 threshold — so no leg of the trade is live today. "Wait" here means standing aside until RSI drops under 50 and MACD rolls below zero while ADX holds above 20. The strategy is built as a fixed-risk setup: a stop 2.6% below entry against a 5.2% take profit, a hard 2-to-1 reward-to-risk ratio, and a maximum 25% position. Position size is set so a full stop-out costs no more than 2.6% of the account. If entries trigger, the support levels at $160 and $152.64 and the resistance level at $170 become the price-based guardrails layered on top. One scope note: the rule set could not be backtested because daily price-data coverage for GH could not be verified within the analysis retry window, so there is no historical trade sample to lean on — the decision rests on the live levels above. That said, the fundamentals give the bearish thesis real fuel: the June 2026 quarter showed a $120.1M net loss, negative $140.7M of free cash flow, and negative equity, while revenue grew 11.0% quarter over quarter to $335.0M with a 65.4% gross margin. Filed ownership data through June 30, 2026 shows roughly $104.4M of net open-market insider selling — direction that aligns with the short thesis even as the price trend does not. Action plan: no position today. Re-check the four entry conditions on each daily close. If price instead breaks and holds above the $170 resistance level while MACD stays positive, the setup is on hold rather than forming, and the thesis needs the next catalysts (below) to reassert itself.

The royalty ruling lands on a company that can't yet afford it

The core of this idea is sound: per Investor's Business Daily (August 24, 2026), a judge ordered Guardant Health to pay royalties to Twinstrand Biosciences after losing a patent dispute over the very tests that generate its revenue. That matters more for GH than it would for most companies because this is not a profitable business absorbing a nuisance cost — it is a company losing money on every dollar of sales. Full-year 2025…

Scores

• Conviction score breakdown: 44
• Thesis support: 60
• Trade readiness: 20
• Risk quality: 50
• Fundamentals trend: 45

Watch items

• GH — RSI (14)
• GH — MACD line (12,26,9)
• GH — ADX (14)
• GH — Close vs resistance
• GH — Quarterly operating cash flow
• GH — Quarterly revenue growth
• GH — Insider net open-market flow
• GH — Net loss
• GH — RSI (14) below 50
• GH — MACD (12,26,9) crossed below 0
• GH — ADX (14) above 20
• GH — EMA (20) crossed above 0
• GH — MACD (12,26,9) crossed above 0